Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03113500
Title Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

mature T-cell and NK-cell lymphoma

Therapies

Etoposide

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone

Doxorubicin

Cyclophosphamide

Prednisone

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.